Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia: The LAPLACE-2 Randomized Clinical Trial

• Autores: Jennifer G. Robinson, Bettina S. Nedergaard, Jonathan Fialkow
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 311, Nº. 18, 2014, págs. 1870-1883
• Idioma: inglés
• Enlaces
  • Texto Completo Ejemplar
• Resumen

  • Importance In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy.

    Objective To evaluate the efficacy and tolerability of evolocumab when used in combination with a moderate- vs high-intensity statin.